Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Moderate to Severe Atopic Dermatitis

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Moderate to Severe Atopic Dermatitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2019

At a glance

  • Drugs RG 6149 (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 06 Feb 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 15 Jan 2019 to 7 Feb 2019.
    • 09 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Dec 2018 to 15 Jan 2019.
    • 10 Dec 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top